{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044353","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.464552+00:00","generated_at":"2026-05-24T06:07:43.692161+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25","bullets":["Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.","FY2024 net loss $51.3M vs $64.7M prior year; Q4 net loss $7.5M vs $16.9M.","Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease due 2Q25.","Phase 1 trial of AN2-502998 for Chagas disease to start mid-2025 in healthy volunteers.","First oncology candidate from boron chemistry platform on track to advance in 2H25."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044353","json":"https://secwatch.observer/filing/0000950170-25-044353.json","markdown":"https://secwatch.observer/filing/0000950170-25-044353.md","text":"https://secwatch.observer/filing/0000950170-25-044353.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/0000950170-25-044353-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/antx-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T06:07:43.692161+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}